Results 61 to 70 of about 397,641 (267)

A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents the first entirely isogenic heart‐on‐chip, unifying cardiomyocytes, fibroblasts, and endothelial cells from a single iPSC source. The platform reveals a critical biological insight: the endothelium actively shields cardiac tissue from drug‐induced toxicity, challenging the predictive accuracy of conventional, avascular models for ...
Karine Tadevosyan   +12 more
wiley   +1 more source

Self- and Goal-Directed Valsalva Maneuver vs Exercise in Eliciting Left Ventricular Outflow Tract Obstruction

open access: yesJACC: Advances
Background: In symptomatic patients with hypertrophic cardiomyopathy (HCM), eliciting left ventricular outflow tract obstruction (LVOTO) is critical. A self-directed Valsalva (SDV) and exercise (EX) are frequent tools used to unmask obstruction in HCM ...
Aakash Bavishi, MD, MSCI   +9 more
doaj   +1 more source

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

open access: yesFrontiers in Cardiovascular Medicine, 2019
Background: Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage revealed upregulation of endothelin (ET1) signaling in both mutants, but TGFβ ...
Yamin Liu   +17 more
doaj   +1 more source

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

open access: yesAdvanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang   +13 more
wiley   +1 more source

Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Milind Y. Desai   +11 more
doaj   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid   +13 more
doaj   +1 more source

The year in cardiology: arrhythmias and pacing. [PDF]

open access: yes, 2020
During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H   +4 more
core   +4 more sources

Gold Nanorods in Cardiac Millitissues: Assessing Mechanical and Contractile Dynamics in a Living Engineering Myocardium Model

open access: yesAdvanced Materials Technologies, EarlyView.
This study presents a novel platform for assessing the active mechanical behavior of living cardiac microbundles through localized nanoindentation, integrated with temperature regulation and dual‐camera imaging systems. The developed system enables quantitative evaluation of dynamic micromechanics in engineered cardiac tissues in vitro, offering ...
Lihua Lou   +4 more
wiley   +1 more source

Weight loss in hypertrophic cardiomyopathy: A clinical case series

open access: yesInternational Journal of Cardiology. Cardiovascular Risk and Prevention, 2023
Background: Obesity is prevalent among patients with hypertrophic cardiomyopathy (HCM). Obese HCM patients have greater wall thickness, LV mass, worse hemodynamic function and NYHA class. Weight loss may favorably influence the HCM phenotype.
Maria C. Reuter   +6 more
doaj   +1 more source

ELABELA Targets Mitochondria to Modulate Heart Development

open access: yesAdvanced Science, EarlyView.
The role of peptide ELABELA (ELA) in cardiomyocyte apoptosis and congenital heart disease (CHD) is unclear. ELA deficiency caused cardiomyocyte apoptosis and CHD. A novel ELA‐APJ‐AKT‐BCL2/BAX axis in regulating mitochondrial function and contributing to CHD pathogenesis was established.
Jian Wang   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy